Markets:

Overview

News

Currencies

International

Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

1.450 -0.140 (-8.81%)

Official Closing Price Updated: 8:00 PM EDT, May 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Which stocks are moving on Monday? ↗

April 14, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 11, 2025

Via Benzinga

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

April 08, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

March 24, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Closing of $2.5 Million Offering

March 18, 2025

From CEL-SCI Corporation

Via Business Wire

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket ↗

March 18, 2025

Via Benzinga

CEL-SCI Announces Pricing of $2.5 Million Offering

March 17, 2025

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 17, 2025

Via Benzinga

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

March 17, 2025

From CEL-SCI Corporation

Via Business Wire

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

March 14, 2025

From CEL-SCI Corporation

Via Business Wire

Stay updated with the stocks that are on the move in today's pre-market session. ↗

February 20, 2025

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

February 20, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

February 18, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

January 14, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Closing of $5 Million Offering

December 31, 2024

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 30, 2024

Via Benzinga

Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November ↗

December 30, 2024

Via Benzinga

Crude Oil Gains 1%; Chicago PMI Falls In December ↗

December 30, 2024

Via Benzinga

US Stocks Open Lower; Dow Tumbles 600 Points ↗

December 30, 2024

Via Benzinga

Topics Stocks

What's Going On With Cel-Sci Shares Premarket On Monday? ↗

December 30, 2024

Cel-Sci announces public offering of 16.13M shares at $0.31 per share, aiming to raise $5M for Multikine development and general purposes.

Via Benzinga

US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking ↗

December 30, 2024

U.S. stock futures declined on Monday after ending lower on Friday. All four index futures slipped in trade.

Via Benzinga

Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket ↗

December 30, 2024

Via Benzinga

CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday ↗

December 30, 2024

Via Benzinga

CEL-SCI Announces Pricing of $5 Million Public Offering

December 29, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Proposed Public Offering of Common Stock

December 27, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

December 12, 2024

From CEL-SCI Corporation

Via Business Wire

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

November 07, 2024

From CEL-SCI Corporation

Via Business Wire

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

October 22, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

October 01, 2024

From CEL-SCI Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.